EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes

Get up to date on current best practices in the treatment of metastatic NSCLC with actionable EGFR mutations, including expert advice on biomarker testing, therapy selection for newly diagnosed and progressive disease, and managing adverse events with EGFR inhibition.

Matthew Gubens, MD, MS Released: March 8, 2021

Thoracic oncologists Enriqueta Felip, MD, and Matthew Gubens, MD, MS, consider evolving practice standards for EGFR-mutated NSCLC in the EU and US.

Enriqueta Felip, MD Matthew Gubens, MD, MS Released: April 20, 2021

Get up to date on the current and future applications of liquid biopsy in the care of patients with EGFR mutation–positive advanced NSCLC.

Christian Rolfo, MD, PhD, MBA, Dr.hc. Released: June 1, 2021

In this expert commentary, gain insights into barriers to osimertinib access worldwide along with future directions in the management of patients with advanced EGFR-mutant NSCLC.

David Planchard, MD, PhD Released: July 29, 2021